Abstract:Several studies suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, it has not been well-characterized in rectal cancer patients who underwent neoadjuvant chemoradiation. This research aims to evaluate the feasibility of microbiome as a marker for rectal cancer and its ability to predict tumor response to neoadjuvant chemoradiation. This study involved a total of 85 locally advanced rectal cancer (LARC) patients who received neoadjuvant chemoradiation in our institution. We collected 85 pre-treatment fecal samples, 84 post-treatment fecal samples from these patients, as well as 31 fecal samples from normal healthy individuals (N) and had all of these samples complete 16S ribosomal RNA sequencing. We characterized gut microbiome, identified microbial markers and constructed treatment response classifier in these patients. Treatment response was determined by the tumor regression grade (TRG) score in which TRG 0-1 as good response (responders, R) and 2-3 as poor response (non-responders, NR). We constructed a classifier tool in 42 patients with random forest model, and validated it in another 43 patients. Community diversity analysis revealed a significant decrease of Chao1 index in LARC versus healthy individuals, and in post-treatment samples versus pre-treatment samples. Clustering and ordination analysis showed a discrepancy in microbiome composition between R and NR, and results were consistent in different sampling timepoints. With linear discriminant analysis, we further confirmed the discrepancy and found that Bifidobacteriaceae and some common "good" genera in Firmicutes were significantly increased in R group, including Roseburia, Anaerostipes and Doreo. To transform this compositional variation into a predicting tool, we constructed a classifying model whose area under curve (AUC) reached 83.18% (CI: 70.48%-95.88%) in the training set, and 73.48% (CI: 58.24%-88.72) in validation set. Reviewing the top 10 genera in the classifier, 6 genera were significant discriminator between R and NR, and 2 between LARC and N. This study revealed the diverse microbiome characteristics in LARC with different response after neoadjuvant chemoradiation. Gut microbiota-targeted biomarkers represent potential noninvasive tools for predicting treatment response in LARC. Further validation is needed in a larger sample of patients.

Advances on biomarkers of sensitivity in locally advanced rectal cancer patients treated with neoadjuvant therapy

Research Progress of Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review

Biomarkers for Predicting the Response to Radiation-Based Neoadjuvant Therapy in Rectal Cancer

Sensitive Biomarkers of Preoperative Radiotherapy in Advanced Rectal Cancer Patients

Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation

[Advances of Optimized Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer].

Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer

A Review of Circulating Tumor DNA as a Biomarker Guide for Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer

Total Neoadjuvant Treatment and PD-1/PD-L1 Checkpoint Inhibitor in Locally Advanced Rectal Cancer

The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer

[Predictive factors for pathological complete response to neoadjuvant therapy in locally advanced rectal cancer: a review of current research]

Advances in Clinical Investigation of Adjuvant Radiotherapy in Rectal Cancer

Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients

Locally Advanced Rectal Cancer: Time for Precision Therapeutics.

Recent Advances in Biomarkers for the Targeted Therapy of Metastatic Colorectal Cancer

Radiomics Approaches for the Prediction of Pathological Complete Response after Neoadjuvant Treatment in Locally Advanced Rectal Cancer: Ready for Prime Time?

Prediction of pathological complete response and prognosis in locally advanced rectal cancer

Gut Microbiome Predicts Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients